We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Hyloris Pharmaceuticals SA | EU:HYL | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.70 | 11.90 | 13.00 | 0.00 | 16:40:00 |
RNS Number:8802O Soldier Limited 20 August 2003 Not for release, publication or distribution in, into or from the United States, Canada, Australia or Japan RECOMMENDED REVISED INCREASED CASH OFFER by KPMG Corporate Finance on behalf of Soldier Limited ("Soldier") for Hamleys plc ("Hamleys") Compulsory acquisition of shares On 4 August 2003, the board of Soldier announced that the Revised Increased Offer had been declared unconditional in all respects. The board of Soldier announces that, by 3.00 p.m. on 19 August 2003, valid acceptances had been received in respect of, in aggregate, 22,522,290 Hamleys Shares representing approximately 97.47 per cent. of the entire existing issued ordinary share capital of Hamleys. Accordingly, the board of Soldier has today commenced the procedure for the compulsory acquisition of all outstanding Hamleys Shares under the provisions of sections 428 to 430F of the Act. The statutory notices will be posted today to Hamleys Shareholders who have not yet validly accepted the Revised Increased Offer pursuant to section 429(4) of the Act. The compulsory acquisition procedure is expected to be concluded on, or shortly after, 1 October 2003. The Loan Note Alternative, under which a maximum of #5 million in nominal value of Loan Notes was available, has now closed. Valid elections have been received under the Revised Increased Offer in respect of #3,883,160 in nominal value of Loan Notes and will be honoured in full. Accordingly, the balance of #1,116,840 will be available under the compulsory acquisition procedure to Hamleys Shareholders who have not yet accepted the Revised Increased Offer. The Revised Increased Offer will remain open for acceptance until further notice. Hamleys Shareholders who have not yet accepted the Revised Increased Offer and who wish to do so are strongly encouraged to take the necessary action set out in the Revised Increased Offer document. Words and expressions defined in the Original Offer Document dated 19 June 2003 and Revised Increased Offer document dated 17 July 2003 shall apply for the purposes of this announcement. Enquiries: Gavin Anderson & Company Tel: 020 7554 1400 Neil Bennett Halldor Larusson Soldier Tel: 020 7479 7313 John Watkinson KPMG Corporate Finance Tel: 020 7311 1000 David McCorquodale Michael McDonagh The availability of the Revised Increased Offer to persons not resident in the UK may be affected by the laws of the relevant jurisdiction. Persons who are not resident in the UK should obtain advice and observe any applicable requirements. The Revised Increased Offer, including the Loan Note Alternative, is not being made, directly or indirectly, in or into, or by use of the mails, or by any means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex or telephone) of interstate or foreign commerce, or of any facility of a national securities exchange, of the United States, Canada, Australia or Japan, and the Revised Increased Offer will not be capable of acceptance by any such means, instrumentality or facility from within the United States, Canada, Australia or Japan. Accordingly, copies of this announcement and any other documents related to the Revised Increased Offer are not being, and must not be, mailed or otherwise distributed or sent in or into the United States, Canada, Australia or Japan and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into or from such jurisdictions as doing so may invalidate any purported acceptance of the Revised Increased Offer by persons in any such jurisdiction. This announcement does not constitute an offer or an invitation to purchase or subscribe for any securities. KPMG Corporate Finance, a division of KPMG LLP which is authorised in the United Kingdom by the Financial Services Authority for investment business activities, is acting for Soldier as financial adviser in relation to the Revised Increased Offer and is not acting for any other person in relation to such offer. KPMG Corporate Finance will not be responsible to anyone other than Soldier for providing the protections afforded to its clients or for providing advice in relation to the contents of this announcement or any transaction or arrangement referred to herein. This information is provided by RNS The company news service from the London Stock Exchange END CASPMMTTMMITBRJ
1 Year Hyloris Pharmaceuticals Chart |
1 Month Hyloris Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions